The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia

Saklamaz, Ali; Çömlekçi, Abdurrahman; Temiz, Aysegul; Caliskan, Sezer; Ceylan, Cengiz; Alacacıoğlu, Ahmet; Yeşil, Sena

doi:10.1016/j.metabol.2004.12.012

Cited by 26 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from nondialysis patients are contradictory. [26][27][28][29] The benefits of atorvastatin in effectively and safely reducing total cholesterol and LDL-C to goal levels in hemodialysis patients were confirmed in our current study. However, more importantly, we present data showing a significant reduction in the atherogenic Lp(a) in dialysis patients receiving low doses of atorvastatin.…”

Section: Effects Of Atorvastatin On Lp(a) and Lipoprotein Profiles Insupporting

confidence: 72%

Effects of Atorvastatin on Lp(a) and Lipoprotein Profiles in Hemodialysis Patients

Joy

Dornbrook-Lavender

Chin³

et al. 2008

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Section: Effects Of Atorvastatin On Lp(a) and Lipoprotein Profiles Insupporting

confidence: 72%

Effects of Atorvastatin on Lp(a) and Lipoprotein Profiles in Hemodialysis Patients

Joy

Dornbrook-Lavender

Chin³

et al. 2008

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…59 These actions of fenofibrate on fibrinogen and PAI-1 antigen levels may decrease the thrombogenic response. Saklamaz et al 60 did not find any significant change in fibrinogen levels during treatment with pravastatin and atorvastatin. However, in the fenofibrate group, fibrinogen levels were significantly decreased in patients with type IIa and type IIb hyperlipidemia.…”

Section: Effects On Hemostasismentioning

confidence: 88%

Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators

Han¹,

Quon²,

Koh³

2005

Hypertension

View full text Add to dashboard Cite

Abstract-Fibric acid is a synthetic ligand of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-␣ that is highly expressed in skeletal muscle and heart, where it promotes ␤-oxidation of fatty acids to mediate hypolipidemic actions. PPAR-␣ regulates expression of key proteins involved in atherogenesis, vascular inflammation, plaque instability, and thrombosis. Thus, PPAR-␣ may exert direct antiatherogenic actions in the vascular wall. Endothelial dysfunction associated with the metabolic syndrome and other insulin-resistant states is characterized by impaired insulin-stimulated nitric oxide production from the endothelium and decreased blood flow to skeletal muscle. Thus, improvement in insulin sensitivity leads to improved endothelial function. This may be an additional mechanism whereby fibrates decrease the incidence of coronary heart disease. Adiponectin is a protein secreted specifically by adipose cells that may couple regulation of insulin sensitivity with energy metabolism and serve to link obesity with insulin resistance. In this review, we discuss the mechanisms underlying the vascular and metabolic effects of fibrates that may act synergistically to prevent or regress atherosclerosis and coronary heart disease.

show abstract

“…However, drug therapy, including statins, is needed for patients who present with higher levels of cholesterol in the bloodstream. 36 Regarding the bioactive compounds present in RBO, several studies have demonstrated their ability to improve the lipid status on animal experimental models, reducing the total plasma cholesterol levels. The hypocholesterolemic effect of refined rice bran oil was compared to that of coconut and canola oils.…”

Section: Studies On Rbo and Its Components Against Dyslipidemiasmentioning

confidence: 99%

Rice Bran Oil

Rigo

Pohlmann

Guterres

et al. 2014

Wheat and Rice in Disease Prevention and Health

View full text Add to dashboard Cite

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia

Cited by 26 publications

References 38 publications

Effects of Atorvastatin on Lp(a) and Lipoprotein Profiles in Hemodialysis Patients

Effects of Atorvastatin on Lp(a) and Lipoprotein Profiles in Hemodialysis Patients

Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators

Rice Bran Oil

Contact Info

Product

Resources

About